Publications by authors named "Solange Soulanoudjingar"
Article Synopsis
- P-ACT has been developed to improve malaria treatment in young children, but its adoption in sub-Saharan Africa is lacking and not widely integrated into treatment guidelines.
- A survey of healthcare personnel in seven African countries revealed that 83% use P-ACT as a first-line treatment, with significant variability in the products used.
- Although P-ACT is common, most formulations do not meet optimal international quality standards, raising concerns about their effectiveness and safety.
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
N Engl J Med
November 2011
Background: An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries.
Methods: From March 2009 through January 2011, we enrolled 15,460 children in two age categories--6 to 12 weeks of age and 5 to 17 months of age--for vaccination with either RTS,S/AS01 or a non-malaria comparator vaccine. The primary end point of the analysis was vaccine efficacy against clinical malaria during the 12 months after vaccination in the first 6000 children 5 to 17 months of age at enrollment who received all three doses of vaccine according to protocol.
Timely treatment of infected children with artemisinin based combination therapies is an essential tool for the effective control and potential elimination of malaria. Until recently only tablet formulations have been available for the treatment of children leading to problems of swallowability, palatability and dosing. In consequence, paediatric drug formulations of artemisinin-based combination therapy (ACT) have been developed, showing a clinically significant improvement of tolerability in young children and of their implementation is an increasingly important public health issue.
View Article and Find Full Text PDFBackground: An effective malaria vaccine, deployed in conjunction with other malaria interventions, is likely to substantially reduce the malaria burden. Efficacy against severe malaria will be a key driver for decisions on implementation. An initial study of an RTS, S vaccine candidate showed promising efficacy against severe malaria in children in Mozambique.
View Article and Find Full Text PDFArticle Synopsis
- The RTS,S/AS01(E) malaria vaccine is being evaluated for infant immunization in Africa, with a study extending follow-up to 19 months to assess safety and efficacy.
- A randomized phase 2 trial involved 511 children in Ghana, Tanzania, and Gabon, comparing different vaccine schedules alongside standard immunizations.
- Results showed higher immune responses in RTS,S/AS01(E) groups compared to controls, with no serious adverse events linked to the vaccine, indicating its potential for safe and effective use in malaria prevention.
Background: Pandemic community-acquired methicillin-resistant Staphylococcus aureus isolates (CA-MRSA) predominantly encode the Panton-Valentine leukocidin (PVL), which can be associated with severe infections. Reports from non-indigenous Sub-Saharan African populations revealed a high prevalence of PVL-positive isolates. The objective of our study was to investigate the S.
View Article and Find Full Text PDFBackground: The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI).
Methods: This phase 2, randomized, open, controlled trial conducted in Ghana, Tanzania, and Gabon evaluated the safety and immunogenicity of RTS,S/AS01(E) when coadministered with EPI vaccines. Five hundred eleven infants were randomized to receive RTS,S/AS01(E) at 0, 1, and 2 months (in 3 doses with diphtheria, tetanus, and whole-cell pertussis conjugate [DTPw]; hepatitis B [HepB]; Haemophilus influenzae type b [Hib]; and oral polio vaccine [OPV]), RTS,S/AS01(E) at 0, 1, and 7 months (2 doses with DTPwHepB/Hib+OPV and 1 dose with measles and yellow fever), or EPI vaccines only.